CD4 and synovial sarcoma: The selective glutaminase variant inhibitor bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) downregulates ECAR and OCR levels of activated CD4 T cells in SS mice [126], reducing lymphocyte infiltrates and thus restoring salivary flow.